CRNX
Crinetics Pharmaceuticals, Inc. · Healthcare
Insiders sold $6.2M of Crinetics Pharmaceuticals, Inc. in the last 12 months and bought none
CRNX over the last year
CRNX after insider buys
3 months after each buy, from the first price a copier could get.
3 buys since 2018 with 3 months of prices.
Every filing
116 insider filings since 2018, newest first
Coelho Rogerio Vivaldi · Director
Stephanie Okey · Director
Jeff E. Knight · Chief Dev., Operating Officer
Jeff E. Knight · COO
Stephen F. Betz · Chief Scientific Officer
Richard Scott Struthers · President and CEO
Coelho Rogerio Vivaldi · Director
Stephanie Okey · Director
Tobin Schilke · CFO
Dana Pizzuti · Chief Med, Dev Officer
Jeff E. Knight · COO
Dana Pizzuti · Chief Med, Dev Officer
Marc Wilson · CFO
Stephen F. Betz · Chief Scientific Officer
Stephen F. Betz · Chief Scientific Officer
Stephen F. Betz · Chief Scientific Officer
Stephen F. Betz · Chief Scientific Officer
Marc Wilson · CFO
Jeff E. Knight · COO
Marc Wilson · CFO
Stephen F. Betz · Chief Scientific Officer
James Hassard · Chief Commercial Officer
Dana Pizzuti · Chief Med, Dev Officer
Marc Wilson · CFO
Jeff E. Knight · COO
Stephen F. Betz · Chief Scientific Officer
Dana Pizzuti · Chief Med, Dev Officer
James Hassard · Chief Commercial Officer
Stephen F. Betz · Chief Scientific Officer
Stephen F. Betz · Chief Scientific Officer
Stephen F. Betz · Chief Scientific Officer
Richard Scott Struthers · President and CEO
Dana Pizzuti · Chief Med, Dev Officer
Richard Scott Struthers · President and CEO
Stephanie Okey · Director
Jeff E. Knight · COO
Dana Pizzuti · Chief Med, Dev Officer
Matthew K Fust · Director
Marc Wilson · CFO
Stephen F. Betz · Chief Scientific Officer
Stephen F. Betz · Chief Scientific Officer
Dana Pizzuti · Chief Med, Dev Officer
Marc Wilson · CFO
Stephen F. Betz · Chief Scientific Officer
Dana Pizzuti · Chief Med, Dev Officer
Stephen F. Betz · Chief Scientific Officer
Stephen F. Betz · Chief Scientific Officer
Richard Scott Struthers · President and CEO
Marc Wilson · CFO
Alan Seth Krasner · Chief Medical Officer
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.